Activation of the Smad signalling pathway by FXa has been suggested as a potential therapeutic target for anticoagulants27, although the contribution of PAR-mediated Smad signalling, stimulated by FXa, to AAA and atherosclerosis pathogenesis has not been studied. Here, F10 is linked to triple-A syndrome.